Keelung Chang Gung Memorial Hospital
Keelung, Taiwan
NCT Number: NCT02904135
To address the challenges of isolating and analyzing rare cells, this study aims to validate the instrumentation, the test protocols, and the analysis of patient's outcome to show the instrument's capability to reproducibly and accurately detect CTCs in cancer patients. In order to facilitate the validation process, investigators will only focus on metastatic patients for whom CTCs supposedly present at higher abundance. Investigators propose to enroll cohorts of metastatic breast cancer patients. Blood samples will be collected from these patients before they start any new line of therapy as determined by their doctors. The specific aims are to isolate, enumerate and analyze the number and/or molecular information of circulating tumor cells in patient blood using microfluidic chip-based sorting, imaging, and molecular profiling techniques. Investigators will use this study to optimize diagnostic instrumentation, test blood processing protocols and CTC analysis algorithm. During this study investigators will collect patients' clinical information related to cancer, as well as the patients' survival status to validate the system's prognosis ability.
Looking for future studies?
Notify Me20 year and older
Female
Observational
Keelung, Taiwan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 years
MiCareo Taiwan Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07329920
Circulating Tumor Cells (CTCs), Neoadjuvant Therapy
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT03928210
Breast Cancer, Breast Diseases
Liestal, Basel-Landschaft, Switzerland
View Trial DetailsNCT02904161
Circulating Tumor Cells (CTCs), Neoplasm Metastasis
Taipei, Taiwan
View Trial DetailsNCT07396259
Circulating Tumor Cells (CTCs), Head and Neck Neoplasms
Taoyuan, City, Taiwan
View Trial Details